Vigabatrin monotherapy in newly diagnosed partial epilepsy: An open multicentre Italian pilot study

M. R. De Feo, O. Mercarelli, M. G. Marciani, S. Striano, M. R. Tata, P. D'Alessandro, G. Cerone, A. Ortenzi, M. Onofri

Research output: Contribution to journalArticle

Abstract

50 patients (18 male) received vigabatrin monotherapy during this study, to assess the efficacy and tolerability of first-line vigabatrin treatment for partial epilepsy. After 1 year, 70% of patients were seizure-free, 17% of patients had a reduction in seizure frequency of at least 50%, and 10% of patients had a reduction in seizure frequency of less than 50%. Only 3% of patients obtained no benefit from the therapy. Drug efficacy did not relate to either baseline seizure frequency or seizure aetiology. Adverse events were usually mild and transitory, and the main adverse events were weight gain and drowsiness. Our results show that vigabatrin may be considered a first-choice drug in newly diagnosed patients with partial epilepsy, owing to its good efficacy and tolerabilty.

Original languageEnglish
Pages (from-to)283-284
Number of pages2
JournalMedical Science Research
Volume26
Issue number4
Publication statusPublished - 1998

Keywords

  • Epilepsy
  • Seizure
  • Vigabatrin

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Vigabatrin monotherapy in newly diagnosed partial epilepsy: An open multicentre Italian pilot study'. Together they form a unique fingerprint.

  • Cite this

    De Feo, M. R., Mercarelli, O., Marciani, M. G., Striano, S., Tata, M. R., D'Alessandro, P., Cerone, G., Ortenzi, A., & Onofri, M. (1998). Vigabatrin monotherapy in newly diagnosed partial epilepsy: An open multicentre Italian pilot study. Medical Science Research, 26(4), 283-284.